Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OSE 2101 companion diagnostic - OSE Immunotherapeutics/GenDx

Drug Profile

OSE 2101 companion diagnostic - OSE Immunotherapeutics/GenDx

Latest Information Update: 25 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GenDx
  • Developer GenDx; OSE Immunotherapeutics
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 19 Jan 2024 Dossier receives positive review from the US FDA for OSE 2101 in Non-small cell lung cancer, before January 2024
  • 19 Jan 2024 OSE Immunotherapeutics plans a phase III trial for Non-small cell lung cancer (Late-stage disease, Second-line therapy and greater) in the US in Q2 of 2024 and extension to Europe in S2 2024
  • 31 Dec 2023 OSE Immunotherapeutics files a dossier to the US FDA for OSE 2101 in Non-small cell lung cancer, before December 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top